{"success":true,"data":{"pressRelease":{"id":"155101","rtpr_id":"nGNXbTmdgC-20260929","ticker":"IMMX","exchange":"NASDAQ","all_tickers":["IMMX"],"title":"Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock","author":"Globe Newswire","published_at":"2026-09-29T11:05:00.146Z","article_body":"LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.\n(“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global\nleader in relapsed/refractory AL Amyloidosis, today announced the pricing of\nan underwritten registered offering of 11,363,637 shares of its common stock\nat a public offering price of $11.00 per share. The gross proceeds from this\noffering are expected to be $125 million, before deducting underwriting\ndiscounts and commissions and offering expenses payable by the Company. The\noffering is expected to close on or about September 30, 2026, subject to the\nsatisfaction of customary closing conditions.\n\nImmix intends to use the net proceeds from this offering to fund NXC-201\ndevelopment, working capital and general corporate purposes.\n\nJ.P. Morgan is acting as the sole book-running manager for the offering. The\noffering included participation from new and existing institutional investors,\nincluding Eventide Asset Management, Janus Henderson Investors, Ridgeback\nCapital Investments L.P., Wellington Management and other leading U.S.\nbiotechnology institutional investors and mutual funds.\n\nThe shares of common stock described above are being offered and sold by the\nCompany pursuant to a shelf registration statement on Form S-3 (File No.\n333-292665), including a base prospectus, filed with the U.S. Securities and\nExchange Commission (the “SEC”) on January 9, 2026, and declared\neffective on January 22, 2026. A prospectus supplement and accompanying\nprospectus describing the terms of the offering will be filed with the SEC and\nwill be available on the SEC’s website located at www.sec.gov. Copies of the\nprospectus supplement and the accompanying prospectus related to this\noffering, when available, may be obtained from J.P. Morgan Securities LLC, c/o\nBroadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York\n11717, or by email at prospectus-eq_fi@jpmchase.com and\npostsalemanualrequests@broadridge.com.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy any of the securities described herein, nor shall there be\nany sale of these securities in any state or other jurisdiction in which such\noffer, solicitation or sale would be unlawful prior to the registration or\nqualification under the securities laws of any such state or other\njurisdiction.\n\nAbout Immix Biopharma, Inc.\n\nImmix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL\nAmyloidosis. AL Amyloidosis is a devastating disease where the immune system,\nthat’s supposed to protect, instead produces toxic light chains, clogging up\nthe heart, kidney and liver, causing organ failure and death. Our lead\ncandidate is sterically-optimized BCMA-targeted chimeric antigen receptor T\n(CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder\n“digital filter” designed to filter out non-specific activation. NXC-201\nteaches the immune system to recognize and eliminate the source of the toxic\nlight chains. NXC-201 is being evaluated in the U.S. multi-center study for\nrelapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a\npotentially registrational design. NXC-201 has been awarded Breakthrough\nTherapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by\nthe US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.\n\nForward Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe federal securities laws. Words such as “may,” “might,” “will,”\n“should,” “believe,” “expect,” “anticipate,” “estimate,”\n“continue,” “predict,” “forecast,” “project,” “plan,”\n“intend” or similar expressions, or statements regarding intent, belief,\nor current expectations, are forward-looking statements. These forward-looking\nstatements are based upon current estimates and assumptions and include\nstatements relating to the offering, including the timing of the closing of\nthe offering, the anticipated use of proceeds therefrom, the potential\nbenefits of the Company’s product candidate CAR-T NXC-201 and the timing and\nresults related to clinical trials, including planned trials. While the\nCompany believes these forward-looking statements are reasonable, undue\nreliance should not be placed on any such forward-looking statements, which\nare based on information available to us on the date of this release. These\nforward-looking statements are subject to various risks and uncertainties,\nmany of which are difficult to predict that could cause actual results to\ndiffer materially from current expectations and assumptions from those set\nforth or implied by any forward-looking statements. Important factors that\ncould cause actual results to differ materially from current expectations\ninclude, among others, risks and uncertainties relating to market conditions;\nthe completion of the proposed offering on the anticipated terms or at all;\nthe risk that the estimates for the number of patients in the U.S. with\nrelapsed/refractory AL Amyloidosis and the market size are not accurate; the\nrisk that further data from the ongoing Phase 1/2 clinical trials for NXC-201\n will not be favorably consistent with the data readouts to date; that no\ndrug product developed by the Company has received FDA pre-market approval or\notherwise been incorporated into a commercial drug product; that success in\nearly phases of pre-clinical and clinicals trials do not ensure later clinical\ntrials will be successful; and those other risks disclosed in the section\n“Risk Factors” included in the Company’s Annual Report on Form 10-K for\nthe fiscal year ended December 31, 2025 and other periodic or current reports\nsubsequently filed with the Securities and Exchange Commission. These reports\nare available at www.sec.gov. Immix Biopharma cautions that the foregoing list\nof important factors is not complete. Immix Biopharma cautions readers not to\nplace undue reliance on any forward-looking statements. Immix Biopharma does\nnot undertake, and specifically disclaims, any obligation to update or revise\nsuch statements to reflect new circumstances or unanticipated events as they\noccur, except as required by law. If we update one or more forward-looking\nstatements, no inference should be drawn that we will make additional updates\nwith respect to those or other forward-looking statements.\n\nContacts:\n\nMike Moyer\nLifeSci Advisors\nmmoyer@lifesciadvisors.com\n\nCompany Contact\nirteam@immixbio.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b46d5687-65de-44df-81d5-e36f2665d8e7)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbTmdgC-20260929","title":"Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock","author":"Globe Newswire","ticker":"IMMX","created":"2026-09-29T11:05:00.146Z","tickers":["IMMX"],"exchange":"NASDAQ","article_body":"LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.\n(“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global\nleader in relapsed/refractory AL Amyloidosis, today announced the pricing of\nan underwritten registered offering of 11,363,637 shares of its common stock\nat a public offering price of $11.00 per share. The gross proceeds from this\noffering are expected to be $125 million, before deducting underwriting\ndiscounts and commissions and offering expenses payable by the Company. The\noffering is expected to close on or about September 30, 2026, subject to the\nsatisfaction of customary closing conditions.\n\nImmix intends to use the net proceeds from this offering to fund NXC-201\ndevelopment, working capital and general corporate purposes.\n\nJ.P. Morgan is acting as the sole book-running manager for the offering. The\noffering included participation from new and existing institutional investors,\nincluding Eventide Asset Management, Janus Henderson Investors, Ridgeback\nCapital Investments L.P., Wellington Management and other leading U.S.\nbiotechnology institutional investors and mutual funds.\n\nThe shares of common stock described above are being offered and sold by the\nCompany pursuant to a shelf registration statement on Form S-3 (File No.\n333-292665), including a base prospectus, filed with the U.S. Securities and\nExchange Commission (the “SEC”) on January 9, 2026, and declared\neffective on January 22, 2026. A prospectus supplement and accompanying\nprospectus describing the terms of the offering will be filed with the SEC and\nwill be available on the SEC’s website located at www.sec.gov. Copies of the\nprospectus supplement and the accompanying prospectus related to this\noffering, when available, may be obtained from J.P. Morgan Securities LLC, c/o\nBroadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York\n11717, or by email at prospectus-eq_fi@jpmchase.com and\npostsalemanualrequests@broadridge.com.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy any of the securities described herein, nor shall there be\nany sale of these securities in any state or other jurisdiction in which such\noffer, solicitation or sale would be unlawful prior to the registration or\nqualification under the securities laws of any such state or other\njurisdiction.\n\nAbout Immix Biopharma, Inc.\n\nImmix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL\nAmyloidosis. AL Amyloidosis is a devastating disease where the immune system,\nthat’s supposed to protect, instead produces toxic light chains, clogging up\nthe heart, kidney and liver, causing organ failure and death. Our lead\ncandidate is sterically-optimized BCMA-targeted chimeric antigen receptor T\n(CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder\n“digital filter” designed to filter out non-specific activation. NXC-201\nteaches the immune system to recognize and eliminate the source of the toxic\nlight chains. NXC-201 is being evaluated in the U.S. multi-center study for\nrelapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a\npotentially registrational design. NXC-201 has been awarded Breakthrough\nTherapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by\nthe US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.\n\nForward Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe federal securities laws. Words such as “may,” “might,” “will,”\n“should,” “believe,” “expect,” “anticipate,” “estimate,”\n“continue,” “predict,” “forecast,” “project,” “plan,”\n“intend” or similar expressions, or statements regarding intent, belief,\nor current expectations, are forward-looking statements. These forward-looking\nstatements are based upon current estimates and assumptions and include\nstatements relating to the offering, including the timing of the closing of\nthe offering, the anticipated use of proceeds therefrom, the potential\nbenefits of the Company’s product candidate CAR-T NXC-201 and the timing and\nresults related to clinical trials, including planned trials. While the\nCompany believes these forward-looking statements are reasonable, undue\nreliance should not be placed on any such forward-looking statements, which\nare based on information available to us on the date of this release. These\nforward-looking statements are subject to various risks and uncertainties,\nmany of which are difficult to predict that could cause actual results to\ndiffer materially from current expectations and assumptions from those set\nforth or implied by any forward-looking statements. Important factors that\ncould cause actual results to differ materially from current expectations\ninclude, among others, risks and uncertainties relating to market conditions;\nthe completion of the proposed offering on the anticipated terms or at all;\nthe risk that the estimates for the number of patients in the U.S. with\nrelapsed/refractory AL Amyloidosis and the market size are not accurate; the\nrisk that further data from the ongoing Phase 1/2 clinical trials for NXC-201\n will not be favorably consistent with the data readouts to date; that no\ndrug product developed by the Company has received FDA pre-market approval or\notherwise been incorporated into a commercial drug product; that success in\nearly phases of pre-clinical and clinicals trials do not ensure later clinical\ntrials will be successful; and those other risks disclosed in the section\n“Risk Factors” included in the Company’s Annual Report on Form 10-K for\nthe fiscal year ended December 31, 2025 and other periodic or current reports\nsubsequently filed with the Securities and Exchange Commission. These reports\nare available at www.sec.gov. Immix Biopharma cautions that the foregoing list\nof important factors is not complete. Immix Biopharma cautions readers not to\nplace undue reliance on any forward-looking statements. Immix Biopharma does\nnot undertake, and specifically disclaims, any obligation to update or revise\nsuch statements to reflect new circumstances or unanticipated events as they\noccur, except as required by law. If we update one or more forward-looking\nstatements, no inference should be drawn that we will make additional updates\nwith respect to those or other forward-looking statements.\n\nContacts:\n\nMike Moyer\nLifeSci Advisors\nmmoyer@lifesciadvisors.com\n\nCompany Contact\nirteam@immixbio.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b46d5687-65de-44df-81d5-e36f2665d8e7)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-29T11:05:00.218369866Z","server_sent_at_ms":1790679900218},"received_at":"2026-09-29T11:05:00.332Z","source_url":null},"analysis":{"id":"143843","press_release_id":"155101","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["equity dilution of ~11.4M shares for a clinical-stage biotech","portion of proceeds earmarked for general corporate purposes"],"eventType":"offering","narrative":"Immix Biopharma priced an underwritten offering of 11,363,637 shares at $11.00 per share for expected gross proceeds of $125 million.\n\nProceeds fund NXC-201 development, working capital and general corporate purposes; J.P. Morgan is sole book-runner with participation from Eventide, Janus Henderson, Ridgeback and Wellington.\n\nNXC-201, the company's BCMA-targeted CAR-T for relapsed/refractory AL Amyloidosis, carries FDA Breakthrough Therapy and RMAT designations and is in the potentially registrational NEXICART-2 study.","sentiment":"mixed","agentHooks":{"shouldPost":true,"suggestedAngle":"$125M raise at $11.00 with top-tier biotech funds fully funding the NXC-201 registrational push — dilution now, binary readout later."},"keyFigures":{"dealValueUsd":125000000,"offeringPrice":11,"sharesOffered":11363637,"customDimensions":{"book_runner":"J.P. Morgan","use_of_proceeds":"NXC-201 development, working capital and general corporate purposes"}},"quotedText":"Immix intends to use the net proceeds from this offering to fund NXC-201 development, working capital and general corporate purposes.","namedEntities":{"people":[{"name":"Mike Moyer","role":"Investor relations contact, LifeSci Advisors"}],"products":["NXC-201"],"companies":[{"name":"Immix Biopharma, Inc.","ticker":"IMMX","relationship":"filer/issuer"},{"name":"J.P. Morgan","relationship":"sole book-running manager"},{"name":"Eventide Asset Management","relationship":"offering participant"},{"name":"Janus Henderson Investors","relationship":"offering participant"},{"name":"Ridgeback Capital Investments L.P.","relationship":"offering participant"},{"name":"Wellington Management","relationship":"offering participant"}],"dollarAmounts":[{"amount":"$125 million","context":"expected gross proceeds of underwritten offering"},{"amount":"$11.00","context":"public offering price per share"}]},"materialImpact":{"score":4,"reasoning":"A $125M underwritten equity raise for a clinical-stage biotech meaningfully dilutes shareholders, but it is priced at $11.00 with strong institutional participation (J.P. Morgan book-runner; Eventide, Janus Henderson, Wellington) and funds the pivotal-track NXC-201 program — a financing positive but dilutive event."},"tickerRelevance":{"others":[],"primary":"IMMX"},"globalImportance":35,"audienceRelevance":30,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"dilutive equity offering with institutional demand","sectorWeight":"biotech financing","issuerAuthored":true}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"mixed","material_impact_score":4,"narrative":"Immix Biopharma priced an underwritten offering of 11,363,637 shares at $11.00 per share for expected gross proceeds of $125 million.\n\nProceeds fund NXC-201 development, working capital and general corporate purposes; J.P. Morgan is sole book-runner with participation from Eventide, Janus Henderson, Ridgeback and Wellington.\n\nNXC-201, the company's BCMA-targeted CAR-T for relapsed/refractory AL Amyloidosis, carries FDA Breakthrough Therapy and RMAT designations and is in the potentially registrational NEXICART-2 study.","key_figures":{"dealValueUsd":125000000,"offeringPrice":11,"sharesOffered":11363637,"customDimensions":{"book_runner":"J.P. Morgan","use_of_proceeds":"NXC-201 development, working capital and general corporate purposes"}},"named_entities":{"people":[{"name":"Mike Moyer","role":"Investor relations contact, LifeSci Advisors"}],"products":["NXC-201"],"companies":[{"name":"Immix Biopharma, Inc.","ticker":"IMMX","relationship":"filer/issuer"},{"name":"J.P. Morgan","relationship":"sole book-running manager"},{"name":"Eventide Asset Management","relationship":"offering participant"},{"name":"Janus Henderson Investors","relationship":"offering participant"},{"name":"Ridgeback Capital Investments L.P.","relationship":"offering participant"},{"name":"Wellington Management","relationship":"offering participant"}],"dollarAmounts":[{"amount":"$125 million","context":"expected gross proceeds of underwritten offering"},{"amount":"$11.00","context":"public offering price per share"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T11:05:06.927Z","global_importance":35,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap","eventGravity":"dilutive equity offering with institutional demand","sectorWeight":"biotech financing","issuerAuthored":true}},"durationMs":6548,"modelName":"glm-5.3-flashx"}}